ZenaTech Directors Hold Steady Stakes Amid Rally, Signaling Confidence in New Defense & Health Tech Pipeline

Insider Holdings Reflect a Cautious Optimism

ZenaTech’s latest Form 3 filing from Corporate Secretary Passley Craig shows a modest holding of 153,327 common shares, leaving the total post‑transaction ownership unchanged. While no new shares were purchased or sold, the maintenance of a sizable stake amid a market that has seen a 12.22 % weekly rally indicates that insiders remain confident in the company’s long‑term trajectory. The filing’s context—price hovering at $2.48 with a negligible -0.01 % change—underscores a period of relative price stability, even as sentiment on social media registers at a modest +6 and buzz at 52 %. For investors, this suggests that insiders are neither aggressively expanding nor withdrawing, which can be reassuring in a sector—cloud‑based medical and safety software—where valuation swings are common.

Comparing Insider Activity Across the Board

In addition to Craig’s holding, a recent company‑wide insider transaction by Piekos Paul (also a director) was logged on 2026‑03‑24. Although this entry reports no new shares (0.00 shares transacted) and a zero price, the post‑transaction total of 54,981 shares confirms that the director’s stake remains intact. The pattern of “holding” moves, rather than active buying or selling, signals a collective inclination to preserve ownership during a phase of rapid product expansion, notably the launch of the counter‑UAS system. For seasoned investors, such behavior can be interpreted as a vote of confidence: insiders are betting on the company’s ability to monetize its new drone‑on‑drone defense platform without diluting their positions.

Implications for Valuation and Growth Prospects

ZenaTech’s price‑earnings ratio of –3.812, combined with a market cap of roughly $140 million, highlights that the company is still operating in a loss‑making phase, typical for a technology firm heavily investing in R&D. However, the recent 12 % weekly gain and a 52‑week high of $7.11 suggest that market sentiment is shifting favorably, especially as the company announces strategic defense contracts. Insiders holding substantial shares amid such a rally may signal that they expect the valuation to continue rising as the company delivers on its quantum computing and drone initiatives. Investors should watch for upcoming earnings releases and milestone announcements from the U.S. Zena AI division, as these will likely influence share price volatility.

Strategic Outlook and Investor Takeaway

With a portfolio that includes cloud‑based medical records software, automated facility management, and a cutting‑edge counter‑UAS platform, ZenaTech sits at the intersection of several high‑growth niches. The lack of significant insider selling in the latest filings suggests that directors believe in the company’s product pipeline and its ability to capture new defense and public safety markets. For investors, the combination of steady insider holdings, positive but moderate social media sentiment, and an active product rollout presents a nuanced picture: a company on the cusp of scaling up that may still be in its early monetization phase. Monitoring insider activity in tandem with quarterly performance will be key to gauging when the market may finally reward the company’s innovative pursuits.